Severe regimen-related toxicities by trial
| . | Trial 2 . | Trial 3 . | Trial 4 . | P value . |
|---|---|---|---|---|
| N = 43 . | N = 16 . | N = 46 . | ||
| Pneumonia | 13 (30%) | 3 (19%) | 11 (24%) | .62 |
| Respiratory failure | 0 | 0 | 2 (4%) | .27 |
| Renal failure | 0 | 1 (6%) | 1 (2%) | .29 |
| Multisystem organ failure | 21 (49%) | 5 (31%) | 9 (20%) | .01 |
| Gastrointestinal hemorrhage | 1 (2%) | 1 (2%) | 1 (2%) | .68 |
| Hemorrhagic cystitis | 14 (30%) | 8 (50%) | 17 (37%) | .47 |
| Infectious | 4 | 2 | 3 | |
| Noninfectious | 10 | 6 | 14 | |
| Posterior reversible encephalopathy syndrome | 7 (16%) | 1 (6%) | 2 (4%) | .14 |
| Death before day 100 | 11 (26%) | 4 (25%) | 3 (7%) | <.01 |
| . | Trial 2 . | Trial 3 . | Trial 4 . | P value . |
|---|---|---|---|---|
| N = 43 . | N = 16 . | N = 46 . | ||
| Pneumonia | 13 (30%) | 3 (19%) | 11 (24%) | .62 |
| Respiratory failure | 0 | 0 | 2 (4%) | .27 |
| Renal failure | 0 | 1 (6%) | 1 (2%) | .29 |
| Multisystem organ failure | 21 (49%) | 5 (31%) | 9 (20%) | .01 |
| Gastrointestinal hemorrhage | 1 (2%) | 1 (2%) | 1 (2%) | .68 |
| Hemorrhagic cystitis | 14 (30%) | 8 (50%) | 17 (37%) | .47 |
| Infectious | 4 | 2 | 3 | |
| Noninfectious | 10 | 6 | 14 | |
| Posterior reversible encephalopathy syndrome | 7 (16%) | 1 (6%) | 2 (4%) | .14 |
| Death before day 100 | 11 (26%) | 4 (25%) | 3 (7%) | <.01 |